**Core Concept**
Tacrolimus is a calcineurin inhibitor used in immunosuppressive regimens to prevent organ rejection in transplant patients. Its plasma levels are crucial for maintaining therapeutic efficacy and minimizing toxicity. The pharmacokinetics of tacrolimus are influenced by various factors, including drugs that interact with its metabolism.

**Why the Correct Answer is Right**
Tacrolimus is primarily metabolized by the cytochrome P450 3A (CYP3A) enzyme system in the liver. Drugs that inhibit CYP3A can increase tacrolimus plasma levels, leading to enhanced immunosuppressive effects and increased risk of toxicity. Conversely, drugs that induce CYP3A can decrease tacrolimus plasma levels, resulting in reduced efficacy.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is not provided, but typically, drugs like erythromycin, ketoconazole, and grapefruit juice inhibit CYP3A and increase tacrolimus plasma levels.
**Option B:** This option is not provided, but drugs like rifampicin, carbamazepine, and phenytoin induce CYP3A and decrease tacrolimus plasma levels.
**Option C:** This option is not provided, but other drugs like metoclopramide, diltiazem, and verapamil may interact with tacrolimus by affecting CYP3A or other mechanisms.

**Clinical Pearl / High-Yield Fact**
When managing immunosuppressed patients, it's essential to monitor tacrolimus plasma levels closely, especially when initiating or adjusting concomitant medications that interact with CYP3A.

**Correct Answer:** A.